BOSTON, Jan. 7, 2021 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of novel therapies for diseases involving mitochondrial
dysfunction, today announced that Reenie
McCarthy, CEO, will participate in pre-recorded
presentations at the following virtual investor conferences in
January:
H.C. Wainwright Virtual BioConnect Conference
Date:
Monday, January 11, 2021
Time: 6:00 am
ET
Stern Investor Relations Corporate Access Event
Date:
Monday, January 11, 2021
Time: 7:00 am ET
A live audio webcast of both presentations will be available on
the Investors & News section of Stealth's website
at https://investor.stealthbt.com/. A replay of the webcasts
will be archived on Stealth's website for 30 days following the
events.
About Stealth
We are a clinical-stage biotechnology company focused on the
discovery, development, and commercialization of novel therapies
for diseases involving mitochondrial dysfunction. Mitochondria,
found in nearly every cell in the body, are the body's main source
of energy production and are critical for normal organ function.
Dysfunctional mitochondria characterize a number of rare genetic
diseases and are involved in many common age-related diseases,
typically involving organ systems with high energy demands such as
the heart, the eye, and the brain. We believe our lead product
candidate, elamipretide, has the potential to treat both rare
metabolic cardiomyopathies, such as Barth, Duchenne muscular
dystrophy and Friedreich's ataxia, rare mitochondrial diseases
entailing nuclear DNA mutations, such as POLG-related disorders, as
well as ophthalmic diseases entailing mitochondrial dysfunction,
such as dry age-related macular degeneration and Leber's hereditary
optic neuropathy. We are evaluating our second-generation
clinical-stage candidate, SBT-272, and our new series of small
molecules, SBT-550, for rare neurological disease indications
following promising preclinical data. We have optimized our
discovery platform to identify novel mitochondria-targeted
compounds which may be nominated as therapeutic product candidates
or utilized as scaffolds to deliver other compounds to
mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-participate-in-upcoming-january-investor-conferences-301202876.html
SOURCE Stealth BioTherapeutics Inc.